Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Battered by compounders on Makena, KV seeks bankruptcy protection

This article was originally published in Scrip

Executive Summary

Blaming the US FDA for some its woes, KV Pharmaceuticals over the weekend revealed it had filed for Chapter 11 bankruptcy protection, hoping to get out from under its debt.

Advertisement

Related Content

AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market
Advertisement
UsernamePublicRestriction

Register

SC018382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel